During the past decade, The Institute for Female Pelvic Medicine and Reconstructive Surgery conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 5 clinical trials were completed, i.e. on average, 31.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Institute for Female Pelvic Medicine and Reconstructive Surgery" #1 sponsor was "Coloplast A/S" with 4 trials, followed by "Ethicon, Inc." with 4 trials sponsored, "Artann Laboratories" with 3 trials sponsored, "GTx" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Institute for Female Pelvic Medicine and Reconstructive Surgery" #1 collaborator was "National Institute on Aging (NIA)" with 3 trials as a collaborator, "Patty Brisben Foundation For Women's Sexual Health" with 1 trials as a collaborator and "Society of Gynecologic Surgeons" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "The Institute for Female Pelvic Medicine and Reconstructive Surgery" are "Pelvic Organ Prolapse" (9 trials), "Stress Urinary Incontinence" (8 trials), "Overactive Bladder" (2 trials), "Urinary Incontinence" (2 trials) and "Cystitis, Interstitial" (1 trials). Many other conditions were trialed in "The Institute for Female Pelvic Medicine and Reconstructive Surgery" in a lesser frequency.

Most popular intervention types in "The Institute for Female Pelvic Medicine and Reconstructive Surgery" are "Device" (13 trials), "Drug" (6 trials), "Other" (4 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "AMDC-USR (iltamiocel)" (1 trials), "Adjustable Continence Therapy for Women (ACT)" (1 trials), "Ajust Adjustable Single-Incision Sling" (1 trials) and "Altis Sling" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Institute for Female Pelvic Medicine and Reconstructive Surgery" are 23 trials for "Female" genders and 4 trials for "All" genders.

Currently, there are NaN active trials in "The Institute for Female Pelvic Medicine and Reconstructive Surgery". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in The Institute for Female Pelvic Medicine and Reconstructive Surgery, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Institute for Female Pelvic Medicine and Reconstructive Surgery, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 5 trials that are defined as “Not Applicable".